|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singal AG, Llovet JM, Yarchoan M, Mehta N,
Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA,
et al: AASLD practice guidance on prevention, diagnosis, and
treatment of hepatocellular carcinoma. Hepatology. 78:1922–1965.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
European Association for the Study of the
Liver, . EASL clinical practice guidelines on the management of
hepatocellular carcinoma. J Hepatol. 82:315–374. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gordan JD, Kennedy EB, Abou-Alfa GK, Beal
E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, et al:
Systemic therapy for advanced hepatocellular carcinoma: ASCO
guideline update. J Clin Oncol. 42:1830–1850. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network.
Electronic address, . simplewheeler@bcm.edu and Cancer
Genome Atlas Research Network: Comprehensive and integrative
genomic characterization of hepatocellular carcinoma. Cell.
169:1327–1341.e23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk
O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G,
Bassaganyas L, Akers N, et al: Identification of an immune-specific
class of hepatocellular carcinoma, based on molecular features.
Gastroenterology. 153:812–826. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zucman-Rossi J, Villanueva A, Nault JC and
Llovet JM: Genetic landscape and biomarkers of hepatocellular
carcinoma. Gastroenterology. 149:1226–1239.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boyault S, Rickman DS, de Reyniès A,
Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti
J, Franco D, et al: Transcriptome classification of hepatocellular
carcinoma is related to gene alterations and to new therapeutic
targets. Hepatology. 45:42–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoshida Y, Nijman SMB, Kobayashi M, Chan
JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K,
Hashimoto M, et al: Integrative transcriptome analysis reveals
common molecular subclasses of human hepatocellular carcinoma.
Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamdy NM, Sallam AM, Elazazy O, Kabel AM,
Salama RM, Gouhar SA, El-Daly SM and Darwish SF: LincRNA-miR
interactions in hepatocellular carcinoma: Comprehensive review and
in silico analysis: A step toward ncRNA precision. Naunyn
Schmiedebergs Arch Pharmacol. 398:14785–14812. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allain C, Angenard G, Clement B and
Coulouarn C: Integrative genomic analysis identifies the core
transcriptional hallmarks of human hepatocellular carcinoma. Cancer
Res. 76:6374–6381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khorsand B, Naderi N, Karimian SS,
Mohaghegh M, Aghaahmadi A, Hadisadegh SN, Owrang M and Houri H:
Comprehensive transcriptomic analysis of hepatocellular carcinoma:
Uncovering shared and unique molecular signatures across diverse
etiologies. Biochem Biophys Rep. 43:1021232025.PubMed/NCBI
|
|
16
|
Yang Z, Wu X, Li J, Zheng Q, Niu J and Li
S: CCNB2, CDC20, AURKA, TOP2A, MELK, NCAPG, KIF20A, UBE2C, PRC1,
and ASPM may be potential therapeutic targets for hepatocellular
carcinoma using integrated bioinformatic analysis. Int J Gen Med.
14:10185–10194. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi F, Zha G, Zhang Y, Liu S, Yang Y, Sun
W, Wang D, Liu Z, Lu Z and Zhang D: Integrative analysis of bulk
and single-cell transcriptomic data reveals novel insights into
lipid metabolism and prognostic factors in hepatocellular
carcinoma. Discov Oncol. 15:5912024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moghimi A, Bani Hosseinian N, Mahdipour M,
Ahmadpour E, Miranda-Bedate A and Ghorbian S: Deciphering the
molecular complexity of hepatocellular carcinoma: Unveiling novel
biomarkers and therapeutic targets through advanced bioinformatics
analysis. Cancer Rep. 7:e21522024.PubMed/NCBI
|
|
19
|
Bisteau X, Caldez MJ and Kaldis P: The
complex relationship between liver cancer and the cell cycle: A
story of multiple regulations. Cancers. 6:79–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schaeffeler E, Hellerbrand C, Nies AT,
Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H
and Schwab M: DNA methylation is associated with downregulation of
the organic cation transporter OCT1 (SLC22A1) in human
hepatocellular carcinoma. Genome Med. 3:822011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heise M, Lautem A, Knapstein J,
Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann
A, Schad A, Gründemann D, et al: Downregulation of organic cation
transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human
hepatocellular carcinoma and their prognostic significance. BMC
Cancer. 12:1092012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herraez E, Lozano E, Macias RIR, Vaquero
J, Bujanda L, Banales JM, Marin JJG and Briz O: Expression of
SLC22A1 variants may affect the response of hepatocellular
carcinoma and cholangiocarcinoma to sorafenib. Hepatology.
58:1065–1073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park S and Hall MN: Metabolic
reprogramming in hepatocellular carcinoma: Mechanisms and
therapeutic implications. Exp Mol Med. 57:515–523. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai P, Feng J, Dong Y, Zhang S, Cao J, Cui
X, Qin X, Yang S and Fan D: Metabolic reprogramming in
hepatocellular carcinoma: An integrated omics study of lipid
pathways and their diagnostic potential. J Transl Med. 23:6442025.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Q, Zhang X, Qi J, Tian X, Dovjak E,
Zhang J, Du H, Zhang N, Zhao J, Zhang Y, et al: Comprehensive
profiling of lipid metabolic reprogramming expands precision
medicine for HCC. Hepatology. 81:1164–1180. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu N, Li H, Tao C, Xiao T and Rong W: The
role of metabolic reprogramming in the tumor immune
microenvironment: Mechanisms and opportunities for immunotherapy in
hepatocellular carcinoma. Int J Mol Sci. 25:55842024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang D, Kroemer G and Kang R: Ferroptosis
in hepatocellular carcinoma: From bench to bedside. Hepatology.
80:721–739. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li
Y, Gao C, Lu H, Wang X, Cao P, et al: A single-cell atlas of the
multicellular ecosystem of primary and metastatic hepatocellular
carcinoma. Nat Commun. 13:45942022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang
Z, Zhang Z, Xie J, Wang C, Chen D, et al: Single-cell landscape of
the ecosystem in early-relapse hepatocellular carcinoma. Cell.
184:404–421.e16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu R, Guo W, Qiu X, Wang S, Sui C, Lian Q,
Wu J, Shan Y, Yang Z, Yang S, et al: Comprehensive analysis of
spatial architecture in primary liver cancer. Sci Adv.
7:eabg37502021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L,
Huang J, Huang X, Huang S, Yu H, et al: Single cell-spatial
transcriptomics and bulk multi-omics analysis of heterogeneity and
ecosystems in hepatocellular carcinoma. NPJ Precis Oncol.
8:2622024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pang W, Wang Y, Lu X, Li M, Long F, Chen
S, Yu Y, Li M and Lin H: Integrated spatial and single cell
transcriptomics identifies PRKDC as a dual prognostic biomarker and
therapeutic target in hepatocellular carcinoma. Sci Rep.
15:148342025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jia G, He P, Dai T, Goh D, Wang J, Sun M,
Wee F, Li F, Lim JCT, Hao S, et al: Spatial immune scoring system
predicts hepatocellular carcinoma recurrence. Nature.
640:1031–1041. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen P, Geng H, Ma B, Zhang Y, Zhu Z, Li
M, Chen S, Wang X and Sun C: Integrating spatial omics and
single-cell mass spectrometry imaging reveals tumor-host metabolic
interplay in hepatocellular carcinoma. Proc Natl Acad Sci USA.
122:e25057891222025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Broutier L, Mastrogiovanni G, Verstegen
MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R,
Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived
organoid cultures for disease modeling and drug screening. Nat Med.
23:1424–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qureshi AA, Wehrle CJ, Ferreira-Gonzalez
S, Jiao C, Hong H, Dadgar N, Arpi-Palacios J, Phong YP, Kim J, Sun
K, et al: Tumor organoids for primary liver cancers: A systematic
review of current applications in diagnostics, disease modeling,
and drug screening. JHEP Rep. 6:1011642024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Airola C, Pallozzi M, Cesari E, Cerrito L,
Stella L, Sette C, Giuliante F, Gasbarrini A and Ponziani FR:
Hepatocellular-carcinoma-derived organoids: Innovation in cancer
research. Cells. 13:17262024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wong AM, Huang H, Wong AM, Leung HHW,
Cheung WWY, Lam YK, Ding X, Zhang L, Chu C, Liu Y, et al:
Patient-derived organoids inform pharmacogenomic vulnerabilities in
liver cancer. JHEP Rep. 7:1014262025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bondarev AD, Jonsson J, Chubarev VN,
Tarasov VV, Lagunas-Rangel FA and Schiöth HB: Recent developments
of topoisomerase inhibitors: Clinical trials, emerging indications,
novel molecules and global sales. Pharmacol Res. 209:1074312024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cai X, Yin G, Chen S, Tacke F, Guillot A
and Liu H: CDK4/6 inhibition enhances T-cell immunotherapy on
hepatocellular carcinoma cells by rejuvenating immunogenicity.
Cancer Cell Int. 24:2152024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ibrahim L, Mohamed RH, Tolba MM, Radwan
SM, Hamdy NM and Elhefnawi M: Unveiling the therapeutic potential
of targeting RRM2 in hepatocellular carcinoma: An integrated in
silico and in vitro study. Funct Integr Genomics. 25:1232025.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cigliano A, Liao W, Deiana GA, Rizzo D,
Chen X and Calvisi DF: Preclinical models of hepatocellular
carcinoma: Current utility, limitations, and challenges.
Biomedicines. 12:16242024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
